サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1655406

悪性中皮腫の世界市場

Malignant Mesothelioma

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
悪性中皮腫の世界市場
出版日: 2025年02月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

悪性中皮腫の世界市場は2030年までに9億7,520万米ドルに達する見込み

2024年に6億8,120万米ドルと推定される悪性中皮腫の世界市場は、2024～2030年の分析期間においてCAGR 6.2%で成長し、2030年には9億7,520万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるプレメトレキセド＆配合剤は、CAGR 6.7％を記録し、分析期間終了時には5億1,860万米ドルに達すると予測されます。シスプラチン＆配合剤セグメントの成長率は、分析期間中CAGR 6.0％と推定されます。

米国市場は推定1億8,840万米ドル、中国はCAGR5.7%で成長予測

米国の悪性中皮腫市場は2024年に1億8,840万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.7%として、2030年までに1億5,050万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.0％と4.8％と予測されています。欧州では、ドイツがCAGR 5.1%で成長すると予測されています。

世界の悪性中皮腫市場- 主要動向と促進要因まとめ

悪性中皮腫とは何か、なぜ深刻な健康問題なのか？

悪性中皮腫は、主に肺、腹部、心臓の内壁を侵し、アスベストへの暴露によって引き起こされる、まれで攻撃的ながんの一種です。潜伏期間が長いため（暴露後数十年経過することが多い）、中皮腫は一般的に進行した段階で診断され、治療が特に困難な疾患です。中皮腫の予後は悪く、治療法も限られているため、研究者やヘルスケアプロバイダーにとって重要な分野となっています。職業性アスベスト暴露と中皮腫発症との関連は、暴露リスク低減のための規制努力にも拍車をかけているが、この疾患は、特に建設や造船などの産業で働く人々にとって、依然として大きな健康上の懸念です。

治療の進歩は中皮腫患者の予後をどのように改善しているか？

悪性中皮腫の治療における進歩は、この課題に直面している患者に新たな希望をもたらしています。手術、化学療法、放射線療法などの従来の治療法は、より正確に病気を標的とする新たな治療法によって補完されています。がん細胞を攻撃するために身体の免疫システムを利用する免疫療法は、一部の中皮腫患者の生存率を延長するという有望な結果を示しています。さらに、がんの増殖に関与する特定の分子経路を阻害する標的治療法も研究されており、より個別化された治療アプローチが可能になる可能性があります。このような革新的な治療法の組み合わせを検討する臨床試験は、現在進行中の研究の重要な焦点であり、これまで治療の選択肢が限られていた患者の転帰を改善することを目指しています。

悪性中皮腫の管理において、患者やヘルスケアプロバイダーはどのような課題に直面していますか？

悪性中皮腫の管理には、早期発見の難しさから始まる大きな課題があります。息切れや胸痛などの中皮腫の症状は非特異的であることが多く、他の疾患と間違われることがあり、診断の遅れにつながります。さらに、一般的に病期が進行した状態で発見されるため、治療の選択肢が制限され、生存率の低下につながります。中皮腫の治療には腫瘍医、胸部外科医、放射線専門医を含む集学的アプローチが必要であるため、専門的治療の利用可能性にも課題があります。多くの患者、特に十分な治療を受けていない地域の患者にとって、実験的治療や臨床試験へのアクセスも限られています。さらに、高額な治療費がこの侵攻性疾患の管理をさらに複雑にしています。

悪性中皮腫市場の成長はいくつかの要因別もたらされる

悪性中皮腫市場の成長は、免疫療法や標的治療の進歩、研究資金の増加、アスベスト関連リスクに対する認識の向上など、いくつかの要因によって牽引されています。より多くの新規治療法が臨床試験に参入し、新薬の承認が拡大するにつれて、中皮腫治療市場は成長すると予想されます。さらに、早期発見の重視と診断ツールの充実により、治療可能な段階で病気を発見できる可能性が高まっています。アスベストへの曝露の危険性に対する認識の高まりと、アスベストの使用制限に向けた規制当局の取り組みも、中皮腫への注目を促し、より優れた予防策や治療法の開発の機会を生み出しています。

セグメント

薬剤クラス別（プレメトレキセド＆配合剤、シスプラチン＆配合剤、カルボプラチン＆配合剤、ゲムシタビン＆配合剤、ビノレルビン＆配合剤、その他薬剤クラス別）

調査対象企業の例（注目の合計43社）

  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP13152

Global Malignant Mesothelioma Market to Reach US$975.2 Million by 2030

The global market for Malignant Mesothelioma estimated at US$681.2 Million in the year 2024, is expected to reach US$975.2 Million by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Premetrexed & Combination Drugs, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$518.6 Million by the end of the analysis period. Growth in the Cisplatin & Combination Drugs segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$188.4 Million While China is Forecast to Grow at 5.7% CAGR

The Malignant Mesothelioma market in the U.S. is estimated at US$188.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$150.5 Million by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.0% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Malignant Mesothelioma Market - Key Trends & Drivers Summarized

What Is Malignant Mesothelioma and Why Is It Such a Serious Health Concern?

Malignant mesothelioma is a rare and aggressive form of cancer that primarily affects the lining of the lungs, abdomen, or heart, caused by asbestos exposure. Due to its long latency period—often several decades after exposure—mesothelioma is typically diagnosed at an advanced stage, making it a particularly difficult disease to treat. The poor prognosis associated with malignant mesothelioma, along with its limited treatment options, has made it a critical area of focus for researchers and healthcare providers. The link between occupational asbestos exposure and the development of mesothelioma has also spurred regulatory efforts to reduce exposure risks, but the disease remains a major health concern, especially for those working in industries like construction and shipbuilding.

How Are Advances in Treatment Improving Outcomes for Mesothelioma Patients?

Advancements in the treatment of malignant mesothelioma are providing new hope for patients facing this challenging diagnosis. Traditional treatment options, such as surgery, chemotherapy, and radiation therapy, have been complemented by emerging therapies that target the disease more precisely. Immunotherapy, which harnesses the body’s immune system to attack cancer cells, has shown promising results in extending survival rates for some mesothelioma patients. Additionally, targeted therapies that inhibit specific molecular pathways involved in cancer growth are under investigation, offering potential for more personalized treatment approaches. Clinical trials exploring the combination of these innovative treatments are a key focus of ongoing research, seeking to improve outcomes for patients who historically have had limited treatment options.

What Challenges Do Patients and Healthcare Providers Face in Managing Malignant Mesothelioma?

The management of malignant mesothelioma poses significant challenges, starting with the difficulty of early detection. Symptoms of mesothelioma, such as shortness of breath and chest pain, are often nonspecific and can be mistaken for other conditions, leading to delayed diagnoses. Moreover, the advanced stage at which the disease is typically detected limits treatment options and contributes to poor survival rates. Another challenge lies in the availability of specialized care, as treating mesothelioma requires a multidisciplinary approach involving oncologists, thoracic surgeons, and radiation specialists. Access to experimental therapies and clinical trials is also limited for many patients, especially those in underserved regions. Additionally, the high costs of treatment further complicate the management of this aggressive disease.

Growth in the Malignant Mesothelioma Market Is Driven by Several Factors

The growth in the malignant mesothelioma market is driven by several factors, including advancements in immunotherapy and targeted treatments, increasing research funding, and improved awareness of asbestos-related risks. As more novel therapies enter clinical trials and regulatory approvals for new drugs expand, the market for mesothelioma treatments is expected to grow. Additionally, greater emphasis on early detection and enhanced diagnostic tools is improving the chances of identifying the disease at a more treatable stage. Growing awareness about the dangers of asbestos exposure, combined with regulatory efforts to limit its use, is also driving attention to mesothelioma, creating opportunities for the development of better preventive measures and treatments.

SCOPE OF STUDY:

The report analyzes the Malignant Mesothelioma market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination, Other Drug Classes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Malignant Mesothelioma - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Asbestos Exposure Propels Growth in Malignant Mesothelioma Treatments
    • Increased Focus on Early Detection Expands Addressable Market for Diagnostic Tools
    • Technological Advancements in Immunotherapy Strengthen the Business Case for Innovative Treatments
    • Growing Awareness of Occupational Health Risks Spurs Demand for Mesothelioma Screening Programs
    • Emergence of Personalized Medicine Expands Opportunities for Tailored Mesothelioma Therapies
    • Advancements in Targeted Therapies Propel Growth in Precision Oncology for Mesothelioma
    • Increased Research & Development in Novel Drug Candidates Generates New Treatment Opportunities
    • Growing Use of Biomarkers in Early Diagnosis Accelerates Demand for Advanced Diagnostic Solutions
    • Rising Focus on Palliative Care for Mesothelioma Patients Sustains Market Growth for Symptomatic Treatments
    • Expansion of Clinical Trials Strengthens Business Case for Innovative Mesothelioma Treatment Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Malignant Mesothelioma Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Premetrexed & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Premetrexed & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Premetrexed & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cisplatin & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cisplatin & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Cisplatin & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Carboplatin & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Carboplatin & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Carboplatin & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gemcitabine & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gemcitabine & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Gemcitabine & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Vinorelbine & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Vinorelbine & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Vinorelbine & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
  • JAPAN
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Japan 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
  • CHINA
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: China 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
  • EUROPE
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Europe 15-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Europe 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
  • FRANCE
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: France 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
  • GERMANY
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Germany 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Italy 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: UK 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Rest of Europe 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 59: Rest of World Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Rest of World Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Rest of World 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030

IV. COMPETITION